Theriva Biologics (TOVX) Stock Statistics & Valuation Metrics

Theriva Biologics has a market cap or net worth of $4.12M. The enterprise value is -$6.30M.

Theriva Biologics has 9,597,952 shares outstanding. The number of shares has decreased by -2.65% in one year.

Theriva Biologics’s return on equity (ROE) is -1.35 and return on invested capital (ROIC) is -66.02%.

The current PE Ratio of Theriva Biologics is ―. Theriva Biologics’s PEG ratio is ―.

In the last 12 months, Theriva Biologics had revenue of 0.00 and earned -25.65M in profits. Earnings per share was -19.03.

In the last 12 months, operating cash flow was -18.07M and capital expenditures -16.00K, giving a free cash flow of -18.09M billion.

Theriva Biologics pays an annual dividend of ―, resulting in a dividend yield of ―

Theriva Biologics upcoming earnings date is Nov 18, 2025, After Close (Confirmed).

Theriva Biologics as a current ratio of 2.15, with Debt / Equity ratio of 11.79%

In the past 12 months, Theriva Biologics has paid 0.00 in taxes.

Theriva Biologics EV to EBITDA ratio is 0.30, with an EV/FCF ratio of 0.45.

Theriva Biologics has $12.12M in cash and marketable securities with $1.25M in debt, giving a net cash position of -$10.87M billion.

Gross margin is 11.69%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Theriva Biologics is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy